Monitor potential long-term adoption of the consensus guidance by German hospitals, which could benefit PICO7 sales, but no near-term catalyst is present. The filing is a routine clinical publication with no immediate trading implications.
Price Chart
Executive Summary
Smith+Nephew announced the publication of new German consensus-based guidance recommending prophylactic single-use negative pressure wound therapy (sNPWT) for high-risk closed surgical incisions, supported by its PICO7 system. The press release is a clinical and health economics publication with no financial results or guidance, despite being filed under Item 2.02 (Earnings).
Key Facts
- New German consensus guidance published in Die Chirurgie recommends prophylactic sNPWT for high-risk closed surgical incisions.
- Guidance cites PICO7 system as a canister-free, portable NPWT device delivering -80 mmHg for up to 7 days.
- Referenced studies show sNPWT reduces length of stay (18 vs. 9 days), staff workload (687.5 vs. 376 minutes), and material costs (€228 vs. €42).
- Smith+Nephew generated $6.2 billion in annual sales in 2025 (from 'About' section, not current quarter).
- No earnings results, EPS, revenue, or guidance are provided in this filing.
Financial Impact
No material financial impact from this clinical publication. The press release is not an earnings report.
Risk Factors
- No material risks identified from this filing; the consensus guidance is non-binding and adoption timelines are uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3324546 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 6-K | $27.80 $26.82 | ▼ −3.53% | ▼ −6.09% | $26.42 (−4.96%) |
Sep 16, 2026 16d ago | 6-K | $27.80 $26.82 | ▼ −3.53% | ▼ −6.09% | $26.42 (−4.96%) |
Sep 11, 2026 21d ago | 6-K | $27.50 $27.56 | ▲ +0.22% | ▲ +0.44% | $26.42 (−3.93%) |
Sep 10, 2026 22d ago | 6-K | $27.62 $27.78 | ▲ +0.58% | ▲ +1.08% | $26.42 (−4.34%) |
Sep 10, 2026 22d ago | 6-K | $27.62 $27.78 | ▲ +0.58% | ▲ +1.08% | $26.42 (−4.34%) |
Sep 9, 2026 23d ago | 6-K | $27.80 $28.06 | ▲ +0.94% | ▲ +1.27% | $26.42 (−4.96%) |
Sep 8, 2026 24d ago | 424B5 | $27.87 $28.01 | ▲ +0.50% | ▲ +1.62% | $26.42 (−5.20%) |
Sep 2, 2026 4w ago | 6-K | $28.66 $27.62 | ▼ −3.63% | ▼ −2.67% | $26.42 (−7.82%) |
Sep 2, 2026 4w ago | 6-K | $28.66 $27.62 | ▼ −3.63% | ▼ −2.67% | $26.42 (−7.82%) |
Sep 1, 2026 4w ago | 6-K | $28.97 $27.80 | ▼ −4.04% | ▼ −4.12% | $26.42 (−8.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access